ISSUE 004 · Oct 6, 2026 · 8 min read

What if one prenatal listen could accelerate heart-failure care?

Use an AI-enabled stethoscope during prenatal and postpartum visits to flag possible ventricular dysfunction, then test a pathway to echocardiography and a joint cardio-obstetric plan within 72 hours—without treating the signal as a diagnosis.

The issue in one sentence

Diagram 01

The 72 hours that turn a signal into care

01Perinatal visit→

0215-sec ECG · sounds→

03AI flag→

04Clinical gate→

05Echo ≤72 h→

06Joint care plan→

07Maternal outcomes

ANM proposed model. It separates a regulated notification from diagnostic echocardiography, making the clinical gate, scheduling, and specialist handoff the testable service.

01Clinical problem · Evidence

A weakening heart can hide behind symptoms that look like normal pregnancy.

Dyspnea, fatigue, and edema from pregnancy-related cardiomyopathy overlap with normal perinatal symptoms. Universal echocardiography is difficult, while symptom-triggered referral can arrive late.

02Technology stack · Proposal

Connect 15 seconds of heart sounds and single-lead ECG to a 72-hour pathway.

A clinician records ECG and phonocardiogram signals with an AI stethoscope. A positive flag passes through a clinical risk gate to reserve echocardiography and cardio-obstetric review. A negative result never blocks referral when red flags persist.

03Research question · Hypothesis

Can it shorten time to confirmed, actionable care—not merely raise detection?

Does an AI-stethoscope-plus-rapid-pathway intervention increase seven-day completion of echocardiography and a joint care plan for true LV dysfunction, while controlling unnecessary echoes and specialist workload?

04First study · Proposal

Twelve maternity sites, 2,400 higher-risk patients, a cluster-randomized trial.

Enroll adults at 28 weeks’ gestation or later, or within six months postpartum, who have red flags such as disproportionate dyspnea, orthopnea, or hypertensive disease. Randomize sites to structured standard triage or AI stethoscope plus a 72-hour pathway. The primary outcome is the proportion of ultimately adjudicated LV dysfunction cases with confirmation and a treatment plan within seven days. Secondary outcomes include echo yield, emergency visits and admissions, serious maternal cardiovascular events, patient burden, and cost per completed diagnosis.

05Defensible data · Hypothesis

The defensible asset is what happens after the signal.

Link heart sounds and single-lead ECG with gestational stage, symptoms, blood pressure, signal quality, echocardiography, referral timing, therapy, admission, and maternal outcomes. The dataset reveals which operational thresholds accelerated useful care—not just which model scored highest.

06Venture thesis · Assumption

Sell a maternal cardiac-assurance episode, not another stethoscope.

Initial customers are tertiary maternity centers, delivery networks, and payers serving higher-risk pregnancies. Bundle device and software access, staff training, positive-screen navigation, reserved echo capacity, and outcome audit per maternity episode. Test risk-sharing only after pathway effectiveness is demonstrated.

Evidence map

The gap between detection and delivered care

1,232 people

Randomized across six Nigerian hospitals; 1,195 completed the baseline visit

4.1% vs 2.0%

LV systolic dysfunction detected with AI stethoscope screening versus usual care

74.7% / 77.5%

FDA-file sensitivity / specificity in general adults—not a pregnancy-specific estimate

205 practices

A 2026 UK implementation trial did not show increased heart-failure detection in general primary care

Evidence

Established evidence versus the untested venture thesis

Established: in a 2024 randomized trial across six hospitals, pregnancy-related LV systolic dysfunction was detected in 4.1% with AI-stethoscope screening versus 2.0% with usual care (OR 2.12). The difference for the 12-lead AI-ECG was not statistically significant. FDA cleared ELEFT in March 2024 as prescription notification software to aid identification of possible LVEF ≤40%; it is neither diagnostic nor intended for disease monitoring, and a negative result does not exclude dysfunction. The regulatory validation cohort had a median age of 64, so pregnancy-specific generalization requires separate evidence. A 2026 implementation trial across 205 UK practices did not increase heart-failure detection in general primary care, underscoring that a strong algorithm is not automatically an effective service. Clinical and economic benefit from the proposed 72-hour pathway therefore remains a venture hypothesis.

Obstetric randomized trial FDA 510(k) record SPEC-AI trial registry 2026 implementation trial

Failure conditions and safety, ethics, and regulatory risks

False reassurance

A negative AI output does not exclude cardiomyopathy. Orthopnea, hypoxemia, chest pain, syncope, persistent tachycardia, or other red flags trigger evaluation regardless of the model.

Confirmation bottleneck

The program fails if more flags do not translate into echo and specialist review within 72 hours. Report slot use, wait time, and positive predictive value together.

Clinical failure condition

Do not scale unless seven-day confirmation and care planning improves by at least 15 percentage points and fewer than 20 excess echoes are required per additional confirmed case.

Domain shift and signal quality

Body habitus, gestational stage, hypertensive disease, placement, and operator experience can shift performance. Predefine unreadable rates, sensitivity, and false negatives by site and subgroup.

Treatment safety in pregnancy

The AI output never automates prescribing. Confirmed cases require joint cardio-obstetric decisions that account for gestational age, lactation, and fetal safety.

Regulatory and liability boundary

Remain within cleared input devices, indications, and clinician-assistive use. Pregnancy-specific thresholds, automated booking or therapy advice, or performance-changing updates may require additional regulatory review and local authorization.

Business failure condition

Reject episode pricing if total screening, navigation, and reserved-capacity costs exceed the value of avoided emergency care and delayed diagnosis, or if eligible-visit adoption stays below 70%.

Bibliography

References

Established facts are separated from research and venture hypotheses that still require validation.

01
Adedinsewo DA, Morales-Lara AC, Afolabi BB, et al. Artificial intelligence guided screening for cardiomyopathies in an obstetric population: a pragmatic randomized clinical trial. Nat Med. 2024;30:2897–2906.
Randomized 1,232 participants. AI-stethoscope screening detected LV systolic dysfunction in 4.1% versus 2.0% with usual care, but the trial did not establish fewer clinical events.PMID 39223284 · NCT05438576
02
ClinicalTrials.gov. Screening for Peripartum Cardiomyopathies Using Artificial Intelligence (SPEC-AI) in Nigeria.
Primary registry and protocol record for the multicenter prospective randomized trial in pregnant or postpartum adults.NCT05438576
03
U.S. Food and Drug Administration. Eko Low Ejection Fraction Tool (ELEFT). 510(k) K233409.
Class II prescription software that flags possible LVEF ≤40% in adults. It is not diagnostic or for monitoring; the general-adult validation reported 74.7% sensitivity and 77.5% specificity.K233409 · Mar 28, 2024
04
Adedinsewo DA, Onietan D, Morales-Lara AC, et al. Contextual challenges in implementing artificial intelligence for healthcare in low-resource environments: insights from the SPEC-AI Nigeria trial. Front Cardiovasc Med. 2025;12:1516088.
Documents implementation bottlenecks in echo capacity, staffing, power, app access, and records—showing why detection alone cannot guarantee care completion.PMID 40134980
05
Kelshiker MA, Bächtiger P, Petri CF, et al. Triple cardiovascular disease detection with an artificial intelligence-enabled stethoscope (TRICORDER) in the UK: a cluster-randomised controlled implementation trial. Lancet. 2026;407:704–715.
Across 205 primary-care practices, implementation did not significantly increase heart-failure detection at 12 months. Although not obstetric, it is a caution that adoption and workflow determine real-world effect.PMID 41619752

The next issue publishes every day at 9 AM KST.All issues